Background Non infectious uveitis (NIU) is frequently associated to systemic auto-immune diseases, ranging from 2% (inflammatory intestinal disease) to 40% (ankylosing spondylitis), while up to 50% of NIU are idiopathic. There is limited data on NIU burden of disease and its associated costs in Spain.
Objectives The purpose of this study was to quantify the yearly costs associated to the management of NIU in Spain.
Methods A systematic literature search tried to find epidemiological data and direct costs of NIU management in Spain. Information gaps were secondarily identified and filled using expert panel consensus: questionnaire consensus development on resource use items to be responded; experts’ individualized response collection; and experts’ consensus agreement on relevant resources whose costs should be calculated. Five experts, two ophthalmologists and three rheumatologists from multi-disciplinary uveitis units at tertiary hospitals, participated. All cost calculations were based on 2011 Spanish National Health System rates for procedures and drug approved prices
Results From the literature search it was found that there were 9398 incident NIU cases in 2011 in Spain of which 55% were female, and 70% aged between 16 and 65 years. Acute Anterior Uveitis (AAU) showed the highest incidence (55%) followed by Posterior Uveitis (PU) and Panuveitis (PnU) (15% each), and Adult Chronic Anterior Uveitis (ACAU), Pediatric Chronic Anterior Uveitis (PCAU) and Intermediate Uveitis (IU) (5% each).
Table 1 shows total associated costs per type of resource used, according to the type of uveitis. Initial drug treatment was associated to the highest cost and included topical cyclopegics, midriatics and steroids, systemic steroids, sulfasalazine, antimetabolites, T-cell inhibitors and TNF-alpha inhibitors. The second highest cost resource was surgical procedures, including cataract, glaucoma treatment, iridotomy and vitrectomy. It also shows total associated costs per patient and per type of NIU. PnU, PU, and AAU management were associated to the highest associated costs.
Conclusions Clinical management of incident NIU in Spain is associated to high yearly costs of resources, mainly originated from initial drug treatment, surgical treatment of complications and diagnostic visits. Prevention of NIU could potentially originate savings to the National Health System
Disclosure of Interest None Declared